EmailWire.Com (Free subscription) | 29/08/2008
(EMAILWIRE.COM, August 29, 2008 ) DALLAS, Texas - Today's Trade Alerts include: Cell Genesys Inc. (Nasdaq: CEGE), Amylin Pharmaceuticals Inc. (Nasdaq: AMLN), Genentech Inc. (NYSE: DNA), Genzyme Corp. (Nasdaq: GENZ), Amgen Inc. (Nasdaq: AMGN) and Gilead Sciences Inc. (Nasdaq: GILD). After a...
Medical,Health News and Articles (Free subscription) | 27/08/2008
Disease/Infection News The Cambridge, Mass.-based biotechnology firm Genzyme border=0> This article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily [...]
Fiercebiotech (Free subscription) | 25/08/2008
Despite a lack of office space or even a complete research team, newcomer ProteoStasis Therapeutics has secured a whopping $45 million in Series A financing. Investors include Boston-based HealthCare Ventures, Fidelity Biosciences, New Enterprise Associates, Novartis Option Fund and Genzyme Ventures. The funds will support research and development for therapies to treat genetic, degenerative and metabolic...
The Boston Business Journal (Free subscription) | 25/08/2008
Genzyme Corp. will be working with a nonprofit research group and an Indian pharmaceutical company to develop new malaria treatments.
Red Orbit (Free subscription) | 25/08/2008
Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&D) organization dedicated to reducing the burden of malaria, announced today a new collaboration with India's Advinus Therapeutics Ltd.
Asiaing.com (Free subscription) | 16/08/2008
GENZYME is one of the world's leading biotechnology companies, dedicated to making a powerful difference in the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe. Genzyme today provides innovative therapies to patients in more than 90 countries.
Red Orbit (Free subscription) | 12/08/2008
By Anonymous United Kingdom - Bayer Schering Pharma AG and Genzyme Europe BV have informed physicians of six infectionrelated deaths, reported from a trial (CALGB10101) in which previously untreated, symptomatic B-cell chronic lymphocytic leukemia (CLL) patients were treated with fludarabine and rituximab followed by alemtuzumab for remission consolidation.
Red Orbit (Free subscription) | 07/08/2008
Genzyme and Isis Pharmaceuticals have initiated a Phase III study of mipomersen in patients with heterozygous familial hypercholesterolemia, a genetic disorder that causes exceptionally high levels of low-density lipoprotein cholesterol.
Medical News Today (Free subscription) | 07/08/2008
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have begun a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH), a genetic disorder that causes exceptionally high levels of LDL cholesterol. It is the first of four new trials the companies plan to initiate by the end of this year, and the second late-stage study...
The Boston Business Journal (Free subscription) | 06/08/2008
Genzyme Corp. and Isis Pharmaceuticals Inc. have launched a late-stage human clinical trial for a drug that treats a genetic disorder that causes extremely high levels of LDL cholesterol.
Red Orbit (Free subscription) | 06/08/2008
Biotechnology Company Experiences 30 Percent Increase in Efficiency by Mobilizing Enterprise Applications Vaultus Mobile Technologies Oonagh O'Regan, 617-399-1105 ooregan@vaultus.com or Schwartz Communications Chuck Tanowitz, 781-684-0770 or Joe Palladino, 781-684-0770 vaultus@schwartz-pr.com Logo: http://www.vaultus.com When Genzyme's European field representatives visit their clients, they will now...
Business Wire (Free subscription) | 05/08/2008
BOSTON--(BUSINESS WIRE)--When Genzyme’s European field representatives visit their clients, they will now have the latest client and sales information from
Nature (Free subscription) | 01/08/2008
Head of R&D, Genzyme Europe.Co-chairman of the European Management Committee, Member of the Corporate Portfolio Management Committee and Head of R&D for Genzyme Europe, Carlo Incerti is responsible for the strategic direction of Genzyme R&D. President of the Board of European Biopharmaceutical Enterprises since
Antitrust & Competition Policy Blog (Free subscription) | 30/07/2008
Posted by D. Daniel Sokol Richard Gilbert (University of California at Berkeley - Economics) offers his thoughts on Innovation Markets after Genzyme/Novazyme. ABSTRACT: The U.S. Federal Trade Commission alleged adverse effects on innovation in about forty percent of all merger...
Business Wire (Free subscription) | 28/07/2008
